[
  {
    "ts": null,
    "headline": "You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth",
    "summary": "UPS and JNJ present strong dividends and attractive valuations. See why these durable companies are great for a buy-and-hold strategy with long-term growth.",
    "url": "https://finnhub.io/api/news?id=24078a95fb45b8c57eb9e573b89cc4fe1a41bc2a9c63ba693eb4cd9f4fbed470",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738572660,
      "headline": "You Deserve Reliable Income: 2 Undervalued Dividends For Long-Term Growth",
      "id": 132520522,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184860418/image_184860418.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "UPS and JNJ present strong dividends and attractive valuations. See why these durable companies are great for a buy-and-hold strategy with long-term growth.",
      "url": "https://finnhub.io/api/news?id=24078a95fb45b8c57eb9e573b89cc4fe1a41bc2a9c63ba693eb4cd9f4fbed470"
    }
  },
  {
    "ts": null,
    "headline": "J&J: CHMP gives the green light for subcutaneous Rybrevant",
    "summary": "Janssen-Cilag International NV announces that the Committee for Medicinal Products for Human Use of the EMA has recommended the extension of the marketing authorization for the subcutaneous...",
    "url": "https://finnhub.io/api/news?id=aa928d2ac8920896e9061fb7158a24d22aeebbb54832061fae0dba49a8bd27f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738569317,
      "headline": "J&J: CHMP gives the green light for subcutaneous Rybrevant",
      "id": 132520088,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Janssen-Cilag International NV announces that the Committee for Medicinal Products for Human Use of the EMA has recommended the extension of the marketing authorization for the subcutaneous...",
      "url": "https://finnhub.io/api/news?id=aa928d2ac8920896e9061fb7158a24d22aeebbb54832061fae0dba49a8bd27f2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR mutated non small cell lung cancer",
    "summary": "Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended an extension of...",
    "url": "https://finnhub.io/api/news?id=6f4843e6b55b2d8da9604e118bbe4d9f43ba6b73596a2177b7e3d17facc3de79",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738559298,
      "headline": "Johnson & Johnson : CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR mutated non small cell lung cancer",
      "id": 132519208,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended an extension of...",
      "url": "https://finnhub.io/api/news?id=6f4843e6b55b2d8da9604e118bbe4d9f43ba6b73596a2177b7e3d17facc3de79"
    }
  }
]